About

Terremoto is a clinical-stage company breaking new ground in the targeted therapy landscape in oncology and genetic disease.

Our Mission

Delivering Medicines with Superior Therapeutic Benefit for Patients

We develop groundbreaking, best-in-class precision therapies to meet urgent patient needs. Through relentless science and deep purpose, we bring life-changing hope to those who need it most.

Enter covalent chemistry.

At Terremoto, we are breaking open the covalent drug universe with the power of lysine-targeted chemistry. In harnessing lysine-based covalency across the disease spectrum, we are focused on developing both best-in-class therapies against known drug targets and first-in-class medicines against the previously undruggable. Our founders helped create this emergent area of science, enabling our team of world-class chemists, biologists and drug developers to pursue a well-defined platform approach and translate treatments to patients as quickly as possible.

We view ourselves as champions for patients. The ultimate driving force behind our work is bringing highly effective medicines to people with devastating diseases as quickly as we possibly can.

Leadership Team

Founded by the Pioneers

With a leadership team and advisory board bringing hundreds of collective years of experience in drug discovery, development, and global regulatory approval, we have the expertise to turn our ambitious vision into life-changing therapies.

James Christensen, Ph.D.

President and Chief Executive Officer

Ronald Shazer, M.D., MBA

Senior Vice President, Head of Clinical Development

Paul Stephensen

Vice President, Finance

Noleen Bonfante

Vice President, Clinical Operations

Michael Corbett, Ph.D.

Executive Director, Head of Technical Operations

Board of Directors

Charles Baum, M.D., Ph.D.

Executive Chairman

James Christensen, Ph.D.

President and Chief Executive Officer

Reid Huber, Ph.D.

Partner, Third Rock Ventures

Scott A. Beardsley

Managing Partner, Novo Holdings Venture Investments

Peter Thompson, M.D.

Co-founder and Director, Terremoto
General Partner, OrbiMed

Founders

Peter Thompson, M.D.

Co-founder and Director, Terremoto
General Partner, OrbiMed Founder

Scientific Advisors

Peter Thompson, M.D.

Co-founder and Director, Terremoto
General Partner, OrbiMed

Reid Huber, Ph.D.

Partner, Third Rock Ventures

Kevin Koch, Ph.D.

President, CEO and CFO, Edgewise
Venture Partner, OrbiMed

Jack Taunton, Ph.D.

Co-founder, Terremoto
Professor, Cellular Molecular
Pharmacology, UCSF

Matthew Jacobson, Ph.D.

Co-founder, Terremoto
Professor, Dept. of Pharmaceutical Chemistry, UCSF

John Link, Ph.D.

Former Vice President, Medicinal Chemistry, Gilead Sciences

Investors

 
© 2026 Terremoto Biosciences